1. Focus on Vaccines: Priorities and Responses to Cape Town Recommendations Retooling Task Force Meeting January 15, 2008

2. Vaccines Focus: Retooling Priorities In 2008, the Working Group on New TB Vaccines will be initiating efforts to:  Evaluate some of the economic aspects of new TB vaccines  Initiate development of target product profiles for new TB vaccines

3. Cape Town Recommendations Recommendation 2: Share information from technical working groups with programmes and partners. In the next 6 months:  Rewrite, publish and disseminate new brochure on TB vaccines  Request RTF to help fund printing and dissemination In the future:  Develop a website on which this information will be available  Pilot an e-newsletter to update the community on recent developments in TB vaccines  Develop community-based materials regarding TB vaccine development and clinical trials

4. Cape Town Recommendations Recommendation 5: Consider the role of the business sector  Initial conversations held with Private Sector Constituency Representative to Coordinating Board  Private Sector Constituency Representative is a member of Economics & Product Profiles Task Force

5. Cape Town Recommendations Recommendation 7: Identify the human resource needs, particularly task-shifting possibilities, that will come with new tools  Too early to determine. Will depend on product profile (ie, pre or post-exposure, delivery mechanism, etc).  Less likely to be a major issue for new vaccines, since plan is to delivery new TB vaccines through existing and future vaccination programmes

6. Cape Town Recommendations Recommendation 8: Continue to share information on lessons learned from other disease control communities that are engaged in retooling  The Working Group will discuss engagement with other vaccine development groups to understand their retooling experience, processes, successes and lessons learned  Request from RTF: commission development of a “template procedure” for definition of product profiles based on existing experience (ie, pneumococcal conjugate vaccine)